2022 World Conference on Lung Cancer (ePosters)-EP08.02-057. Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance

Pdf Summary

This document discusses a study conducted to analyze the resistance mechanisms acquired after treatment with aumolertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), and explore the feasibility of aumolertinib resistance-related therapeutic regime. The study aims to determine the mechanism of resistance to second-line aumolertinib and explore the possibility of combination treatments. <br /><br />The most common mechanisms of resistance to aumolertinib were found to be acquired EGFR C797S mutation and aberration in PIK3CA bypass track. This is different from previous studies on osimertinib, another EGFR TKI, where the most common mechanisms of resistance were MET amplification and acquired EGFR C797S mutation. <br /><br />The study is designed as a prospective, open-label, single-arm study with the primary endpoint being the mechanism of resistance to aumolertinib. The secondary endpoint is to explore the feasibility of combination treatments associated with aumolertinib resistance. Patients will be followed up with RECIST V1.1 assessments every 6 weeks until disease progression. The study includes patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have confirmed EGFR T790M mutation and an ECOG PS score of 0-2. Patients will receive aumolertinib as the treatment. <br /><br />The study also provides information on patient selection criteria, study endpoints, and goals. The primary objective is to determine the mechanism of resistance, measured by progression-free survival (PFS), while the secondary objectives include exploring the feasibility of combination treatments, assessing PFS2, objective response rate (ORR), disease control rate (DCR), and safety. The study is currently enrolling participants and is sponsored by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.<br /><br />In conclusion, this study aims to understand the resistance mechanisms to aumolertinib and explore potential combination treatments for patients who have progressed from previous EGFR TKI therapies.

Asset Subtitle

Lingxin Feng

Meta Tag

Speaker Lingxin Feng

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

aumolertinib

resistance mechanisms

EGFR TKI

acquired EGFR C797S mutation

PIK3CA bypass track

combination treatments

osimertinib

MET amplification

prospective study

non-small cell lung cancer